The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...
Supported by the CHORD trial, this AAV vector-based therapy delivers a working copy of the OTOF gene and restores otoferlin protein production.
The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...
The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...
The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
Morning Overview on MSN
Gene therapy restored hearing in 90% with OTOF deafness, study says
A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...
Researchers confirm gene therapy can reverse inherited deafness, offering hope to millions born with genetic hearing loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results